Biomanufacturing Symposium at BIOTECHNICA 2009

Collaboration between drug developers and manufacturers
Process validation plays an important role in the early stages of development
Special factors relating to the development of biosimilars
BIOTECHNICA 2009
(6 – 8 October)

Following its successful premiere in 2008, the Biomanufacturing Symposium will be making a repeat appearance at this year’s BIOTECHNICA. Targeted specifically at developers and manufacturers, this one-day event will provide an effective framework for communication between the biotechnology and pharmaceutical sectors. The Symposium will be organized by Capgemini Consulting in collaboration with Deutsche Messe, Hannover. In a series of brief lectures leading experts will address current biomanufacturing issues and discuss potential solutions with the attendees. In 2009 the focus will be on the following topics: collaboration between drug developers and manufacturers; the importance of process validation in the early stages of development; and special factors relating to the development of biosimilars.

Collaboration strategies

The collaboration between developers and manufacturers of bio-pharmaceuticals raises an important question: To what extent is manufacturing know-how a prerequisite for successful technology transfer? Three leading experts (working in the fields of product development, pharmaceuticals and biotechnology respectively) will join forces to answer this question and discuss other issues relating to strategic partnering, licensing, outsourcing and capacity planning.

Process validation

Complex development processes (i.e. those involving various parties) raise further questions: How important is the early integration of validation tools during the development of new active substances? Should validation and monitoring be applied during the initial method development stage? These questions have a decisive impact on reproducibility and on the success of planned technology transfer and biomanufacturing. Such issues will be on the agenda during the second block of lectures at the Biomanufacturing Symposium.

Biosimilars

Biosimilars pose a serious challenge to process developers. Due to their special status (somewhere between generics and innovative bio-pharmaceuticals) these follow-on products occupy a grey area. Which expression systems can be used to create protein agents, and what impact do these systems have on clinical trials and regulatory procedures? This question will be discussed during the final plenary session of the Biomanufacturing Symposium.

The Biomanufacturing Symposium will take place in the Convention Center (CC), Hall 3B, at the Hannover Exhibition Grounds on 7 October (11.30 a.m. to 6.15 p.m. The conference language is English. Attendees are required to register in advance. Further information on the program and the relevant terms and conditions can be found at www.biotechnica.de/60331

About BIOTECHNICA

BIOTECHNICA Hannover is the flagship fair for the European biotechnology sector. It focuses on all areas of biotechnology – basic research, equipment, bioinformatics, services and applications (pharmaceuticals/medicine, industry, nutrition, agriculture, chemicals and environmental engineering). Since 1985 BIOTECHNICA has been staged by Deutsche Messe AG at the Hannover Exhibition Grounds. Successful spin-off events have become established in Asia (BIOTECH CHINA) and the USA (BIOTECHNICA AMERICA).

About Capgemini und Capgemini Consulting

Capgemini is a global leader in consulting, technology, outsourcing and local professional services. The company helps companies to accomplish change and create the necessary scope for growth. Capgemini employs a work force of 90,000 in 30 countries and reported revenues of more than €8.7 billion in 2008.

Part of the Capgemini Group, Capgemini Consulting specializes in Business Transformation®. Over a period of many decades the company’s multidimensional Business Transformation Framework has delivered measurable and sustainable benefits for its clients. More than 4,000 strategy and management consultants contribute their commitment and skills with the goal of facilitating change and innovation in organizations and individuals. Since 1995 the biotechnology team within the Capgemini Consulting Life Science Practice has been providing continuous support in connection with strategy and management questions. The list of customers includes biotech enterprises, pharmaceuticals companies and public sector bodies (e.g. government departments and bioregions).

Number of characters (including spaces): 4,519

Additional press releases and photos can be downloaded from:
www.biotechnica.de/pressservice

Contacts

Deutsche Messe AG:
Katharina Siebert
Tel.:+49 511 89-31028
E-mail: katharina.siebert {at} messe(.)de